4303.0: Tuesday, October 23, 2001 - 4:30 PM

Abstract #31218

Digital screening for diabetic retinopathy: a risk reduction program

Lawrence M. Merin, RBP, FIMI, Department of Ophthalmology and Visual Sciences, Vanderbilt University, 8103 Medical Center East, Nashville, TN 37232, 615-936-3247, lawrence.merin@mcmail.vanderbilt.edu

Diabetic retinopathy is one of the most catastrophic complications of hyperglycemia and is the leading cause of adult blindness in the United States. The enormous costs of social support for patients blinded by retinopathy, and the inestimable damage to the lives of patients and their families, can usually be avoided if the recommended frequency of dilated retinal examinations and laser photocoagulation is followed. The effectiveness of laser in stabilizing vision is well known, but positive outcomes rely on early identification of treatable lesions. Despite urgings by physicians, diabetic educators and public service announcements in mass media, nearly half of the known diabetics in the U.S. fail to obtain regular dilated eye examinations. Impediments to proper care include expense, time, discomfort, logistical problems, and a failure to appreciate that retinopathy can be present without visual symptoms. An accurate and cost-effective approach to diabetic retinopathy screening utilizes high resolution true digital retinal cameras, a simple protocol for image acquisition, electronic transmission of images to a dedicated reading center, and speedy triage of patients based upon proven assessment criteria. By taking the technology directly to the patient in a primary care, diabetes or community health clinic, this model reduces the costs of conventional physician-provided ophthalmoscopy, facilitates attainment of the examination schedule proposed by both the ADA and the AAO, and results in positive visual outcomes.

Learning Objectives: At the conclusion of the session, the participant will be able to describe the natural history of diabetic retinopathy, explain treatment options, describe the acquisition protocol, and discuss quality assurance.

Keywords: Diabetes, Screening

Presenting author's disclosure statement:
Organization/institution whose products or services will be discussed: None
I do not have any significant financial interest/arrangement or affiliation with any organization/institution whose products or services are being discussed in this session.

The 129th Annual Meeting of APHA